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Abstract 
Heterocyclic aromatic amines (HCA) are carcinogenic mutagens formed during cooking of protein-rich 
foods. HCA residues adducted to blood proteins have been postulated as biomarkers of HCA 
exposure. However, the viability of quantifying HCAs following hydrolytic release from adducts in vivo 
and correlation with dietary intake are unproven. To definitively assess the potential of labile HCA-
protein adducts as biomarkers, a highly sensitive UPLC-MS/MS method was validated for four major 
HCAs: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,8-dimethylimidazo[4,5-
f]quinoxaline (MeIQx), 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (4,8-DiMeIQx) and 2-amino-
3,7,8-trimethylimidazo[4,5-f]quinoxaline (7,8-DiMeIQx). Limits of detection were 1-5 pg/ml plasma and 
recoveries 91-115%. Efficacy of hydrolysis was demonstrated by HCA-protein adducts synthesised in 
vitro. Plasma and 7-day food diaries were collected from 122 fasting adults consuming their habitual 
diets. Estimated HCA intakes ranged from 0-2.5 mg/day. An extensive range of hydrolysis conditions 
was examined for release of adducted HCAs in plasma. HCA was detected in only one sample (PhIP, 
9.7 pg/ml), demonstrating conclusively for the first time that acid-labile HCA adducts do not reflect 
dietary HCA intake and are present at such low concentrations that they are not feasible biomarkers 
of exposure. Identification of biomarkers remains important. The search should concentrate on 
stabilised HCA-peptide markers and use of untargeted proteomic and metabolomic approaches. 
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1. Introduction 
Heterocyclic aromatic amines (HCA) are formed during combustion of tobacco and cooking of protein-
rich foods, particularly meat and fish, which provide creatin(in)e and other precursors such as amino 
acids, sugars or other aldehydes (Cheng et al., 2006; Puangsombat et al., 2012; Aaslyng et al., 
2013). 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), 2-amino-3,8-dimethylimidazo[4,5-
f]quinoxaline (MeIQx) and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (4,8-DiMeIQx) are three of 
the most abundant HCAs in cooked meat and fish (Lynch et al., 1995; Zhang et al., 2013) although 
many others have been identified (Ni et al., 2008). Their formation in the parts-per-billion 
concentration range on the surface of food is highly dependent upon the type of food and the method 
and degree of cooking, making estimation of HCA dietary exposure difficult (Alexander et al., 2002). 
HCAs have been extensively studied; particularly their production, metabolism (Turesky et al., 2002), 
formation of adducts with DNA (Schut and Snyderwine, 1999) and protein (Peng et al., 2012), their 
quantification (Murkovic, 2011) and implications for human health. There is strong evidence from 
animal models (Adamson et al., 1990; Shirai et al., 1997; Paulsen et al., 1999) and in vitro studies 
(Gooderham et al., 2007) of the carcinogenic and mutagenic properties of HCAs. Although several 
case-control studies in humans have reported positive associations between consumption of well-
done red meat (assumed to contain elevated HCA concentrations) and incidence of colon, breast, 
lung and gastric cancers (Sinha, 2002), evidence correlating HCA dietary intake and cancers can be 
equivocal (Sugimara et al., 2004; Tang et al., 2013). 
    To overcome limitations of estimating HCA intake by food frequency questionnaires, direct 
measurement of in vivo biomarkers of HCA exposure is desirable. Whilst urine HCA metabolic profiles 
have been described (Holland et al., 2004), urinary biomarkers are transient, representing only daily 
HCA exposure and allowing intermittent intake to go undetected (Turesky and Le Marchand, 2011). 
Long-term biomarkers of HCA exposure are still needed for use as internal dosimeters in 
epidemiological studies. As with many environmental and dietary toxicants (Rappaport et al., 2012), 
blood protein adducts have been postulated as potential biomarkers. HCAs are subject to in vivo 
metabolic activation via N-hydroxylation of their exocyclic amine groups. The resulting reactive 
intermediates bind to cysteine residues of proteins via sulfinamide linkages (Peng and Turesky, 2014; 
Chepanoske et al., 2004). The arylsulfinamide bonds formed between HCAs and cysteine in 
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haemoglobin (Hb-Cys93) and serum albumin (HSA-Cys34) are known to be labile, undergoing 
hydrolysis under conditions commonly used to digest proteins. This labile characteristic has been 
used to monitor exposure to other carcinogenic aromatic amines following hydrolytic release of the 
intact compound from haemoglobin adducts (Gan et al., 2004). 
Several studies have demonstrated the liberation of HCAs from protein or DNA adducts and their 
subsequent quantification as the intact HCA. However, these are almost exclusively studies of in vitro 
HCA-adducts created using liver microsome systems (Lynch et al., 1991) or conjugation using 
reactive intermediates (Peng and Turesky, 2011; Wang et al., 2015). Furthermore, some studies are 
applied to cell cultures (Crosbie et al., 2000) or extraction procedures from plasma (Lezamiz et al., 
2008) or proteins (Busquets et al., 2006) fortified with free HCAs but not to incurred samples 
containing known HCA-protein adducts.  The concentration of adducts in such in vitro studies may be 
significantly greater than would be expected in vivo, and the efficacy of hydrolysis procedures to 
release protein-adducted HCAs is unknown in those studies which employ only fortification with free 
HCAs. Only one study (Magagnotti et al., 2000) has claimed to quantify an HCA adducted to blood 
proteins following its release by hydrolysis from the blood of human subjects consuming normal diets. 
Magagnotti observed 1.5 pg PhIP/mg HSA (equivalent to approximately 70 pg PhIP/ml plasma) in 
meat-eating participants after mild acid hydrolysis and liquid-liquid extraction followed by 
immunoaffinity chromatography clean-up. PhIP concentrations ten-fold lower were detected in 
vegetarian participants. PhIP derived from haemoglobin adducts was half that observed from HSA 
adducts. The fact that this study has not been reproduced in the following years suggests that release 
and quantification of protein-adducted HCAs is problematic. The lack of literature concerning labile 
HCA adducts and the focus of recent studies on HCA-DNA adducts and characterisation of stable 
HCA-peptide adducts support this idea. However, the candidacy of labile HCA-protein adducts as 
biomarkers of HCA exposure has not been conclusively ruled out or, it would appear, subjected to 
systematic study. PhIP-albumin adducts, in particular, continue to be proposed as potential 
biomarkers (Turesky and Le Marchand, 2011). The current study aims to conclusively assess the 
suitability of labile HCA adducts in plasma as biomarkers of dietary HCA exposure by employing high 
sensitivity mass spectrometry, in vitro HCA-protein control adducts to evaluate efficacy of hydrolysis, 
and a cohort of human blood samples accompanied by detailed HCA dietary intake information 
collected in a cross-sectional study of participants consuming their habitual diets. 
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2. Materials and methods 
2.1. Materials 
Reference standards 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,8-dimethyl-
imidazo [4,5-f]quinoxaline (MeIQx), 2-amino-3,4,8-trimethylimidazo [4,5-f]quinoxaline (4,8-DiMeIQx), 
2-amino-3,7,8-trimethylimidazo [4,5-f]quinoxaline (7,8-DiMeIQx) and deuterium labelled internal 
standards (I.S.) D3-PhIP, D3-MeIQx and D3-4,8-DiMeIQx (each isotopically labelled at the methyl 
group at the N-1 position of the imidazo ring) were purchased from Toronto Research Chemicals 
(North York, ON, Canada). Mixed standard solutions prepared in LCMS grade methanol were stored 
at 4◦C. Human liver microsomes (50 donor pool) were obtained from Invitrogen Ltd (Paisley, UK), 
recombinant human sulfotransferase 1A1 from US Biological (Swampscott, MA, USA), and NADPH 
regenerating system from BD Biosciences (Oxford, UK). Unless stated, all other chemicals, including 
human haemoglobin (H7379) and human serum albumin (A3782) were obtained from Sigma-Aldrich 
(Dorset, UK). Slide-A-Lyzer dialysis cassettes and Pierce BCA Protein Assay Kit were obtained from 
Thermo Fisher Scientific (Rockford, IL, USA). Oasis MCX strong cation exchange solid phase 
extraction cartridges (1 ml, 30 mg) were obtained from Waters Corporation (Milford, MA, USA). 
2.2. Cross-sectional study 
2.2.1. Participants and food diaries  
Healthy cross-sectional study participants, recruited via poster and email advertisement and through 
word-of-mouth, were given full study information and screened for eligibility. Those under 18 years 
were excluded, as were smokers, due to potential exposure to polycyclic aromatic hydrocarbons. 
Eligible participants provided written, informed consent. They received 7-day food diaries and detailed 
instructions on recording their dietary intake, with particular emphasis on describing cooking methods 
and 'doneness' level of any meat consumed. Participants recorded their dietary intake for seven 
consecutive days and returned within two days of completing their diary. The study was conducted 
according to the guidelines laid down in the declaration of Helsinki and all procedures involving 
human subjects were approved by the School of Medicine, Dentistry and Biomedical Sciences 
Research Ethics Committee of Queen’s University Belfast. 
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2.2.2. Blood collection 
Participants fasted (water only allowed) for at least 12 h prior to attending the cross-sectional study 
visit to ensure removal of free circulating HCAs from plasma. Participants provided a 50ml blood 
sample, collected in anticoagulant plasma tubes and serum tubes, by staff trained in venepuncture. 
Serum tubes were allowed to coagulate at room temperature for 1 h while plasma tubes were 
refrigerated. Serum and plasma were obtained by centrifugation, buffy coat being discarded from 
plasma tubes. Serum and plasma were aliquotted and stored at -80°C for long-term storage and at -
20°C during the analysis phase. 
2.2.3. Food diary review 
Completed food diaries were reviewed by a member of the research team asking participants to 
confirm the food portions they recorded using a photographic Portion Size Atlas (Nelson et al., 2002). 
Participants were also asked to clarify the cooking methods used and to describe the ‘doneness’ level 
of any meat consumed by matching it to a series of published colour-printed 'meat doneness' pictures, 
including beef burgers, bacon and steak (Sinha et al., 1998a; 1998b), and steak 'doneness' pictures 
produced by the research team and described elsewhere (Chan et al., 2013). The additional 
information obtained by this review of food diaries improved the accuracy of the estimated HCA 
dietary intake. 
2.2.4. Food diary analyses 
Dietary HCA intake was determined by analysing information from the self-reported food diaries using 
the dietary analysis program WISP v3.0 (Tinuviel, UK). Certain food items in WISP are available to 
select under various food codes which differ by cooking method. The database was updated, for the 
purposes of this study, with additional meat food codes based on cooking methods and varying levels 
of ‘doneness’. Nutrient data within WISP were also updated to include values for the commonly 
consumed HCAs (MeIQx, DiMeIQx and PhIP) assigned to the newly updated food codes and cooking 
methods. Information on HCA content was obtained from the CHARRED online database (US 
National Cancer Institute, 2015) and a second published database (Alaejos and Afonso, 2011). HCA 
values were applied directly to 'meat only' food codes and, for composite dishes, were calculated from 
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disaggregated meat content using published data (Fitt et al., 2009) or estimated from average 
percentage meat content in commercial dishes available from UK supermarkets. Meat 'doneness' 
level for composite dishes was assumed to be 'well done' for the present analyses. Consequently, 
mean total HCA intake (ng/day) and intake of the individual HCAs (MeIQx, DiMeIQx and PhIP) were 
estimated from detailed self-reported information on type, amount, cooking method and 'doneness' of 
meat consumed. 
2.3. Preparation and characterisation of in vitro HCA-protein adducts 
To act as positive controls in the analysis of HCA-protein adducts, PhIP and MeIQx were conjugated 
in vitro to human serum albumin and haemoglobin using human hepatic microsomes essentially as 
described by Lynch et al. (1993). Human microsomes were selected over the more commonly used 
rodent microsomes because significant species differences in catalytic activity and regioselectivity of 
HCA metabolism have been shown and adducts which closely mimic the structures formed by human 
metabolism in vivo were required for this study (Turesky et al., 2002; Cheung et al., 2005). Proteins 
(10 mg) were mixed with HCA (25 µg), human liver microsomes (50 µl) and a NADPH regenerating 
system (100 µl NADP+ solution A and 20 µl enzyme solution B) in a total volume of 1 ml Tris-HCl 
buffer (50mM, pH 7.6). Reagents were mixed in a 37°C shaking water bath for 18 h then centrifuged 
at 100 000 g for 1 h at 4°C. Supernatants were diluted with 3 ml deionised water before exhaustive 
dialysis against saline (4 L changed seven times over 72 h) to remove unbound HCAs. The inclusion 
in the microsomal reaction mixture of a Phase II enzyme, sulphotransferase-1A1 (with adenosine 3-
phosphate 5-phosphosulfate), was investigated but no increase in adduction of PhIP to HSA was 
evident. Negative control reactions, omitting the liver microsomes, were also conducted to 
demonstrate that HCA adduction was via covalent binding following enzymatic metabolism rather than 
non-specific adsorption to the proteins. Total protein concentrations were determined by bicinchoninic 
acid colourimetric test using protein-specific standard curves. Concentrations of acid-labile HCAs 
adducted to proteins were determined by LC-MS/MS as described below following acid hydrolysis 
(0.8M HCl at 80°C for 2 h) and liquid-liquid extraction with ethyl acetate. 
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2.4. Extraction and quantification of HCAs from blood 
A highly sensitive method was developed and validated for the hydrolysis, extraction and 
quantification by liquid chromatography tandem mass spectrometry of HCAs in human blood. 
2.4.1. Adduct hydrolysis methods 
A pooled plasma sample was prepared from 13 cross-sectional study participants in the highest tertile 
of HCA intake based on food diaries described below. The estimated mean daily HCA intake 
associated with this pooled sample was 1.2 µg HCA/day. Nine acid and alkaline hydrolysis conditions 
were assessed for release of protein-adducted HCAs from this pooled plasma prior to extraction and 
quantification as described below. Conditions were based on literature reports of HCA hydrolysis from 
cooked foods, hair and in vitro blood protein and DNA adducts (Table 1). 
2.4.2. HCA extraction method 
An unusually large plasma sample size (1 ml) was used to maximise method sensitivity. Plasma 
samples, in 50ml polypropylene centrifuge tubes, were fortified with internal standards (D3-PhIP, D3-
MeIQx and D3-4,8-DiMeIQx) at 2 pg/ml and hydrolysed with 10 ml of acid or alkali in a shaking water 
bath for between 1 and 18 h as listed in Table 1. Acid hydrolysed samples were adjusted to pH 11.5 ± 
0.5 with 10M NaOH. Double liquid-liquid extraction was performed using 9 ml and 8 ml LCMS grade 
ethyl acetate (mixing for 60 sec, centrifuge 1500 g for 10 min). Combined supernatant was reduced to 
approximately 5 ml under nitrogen in a 45°C water bath then acidified with 10 µl glacial acetic acid. 
Extracts were applied to MCX cation exchange solid phase extraction cartridges previously 
conditioned with 1 ml each of 5% aqueous ammonia in methanol, 2% acetic acid in methanol, and 
100% methanol. Loaded columns were washed with 1 ml each of 40mM HCl in methanol, 100% 
methanol, and 2% aqueous ammonia in 15% methanol, then eluted with 1 ml of 5% aqueous 
ammonia in methanol (Holland et al., 2004). Eluates were evaporated to dryness at 55°C under 
nitrogen, reconstituted in 100 µl of 30mM ammonium formate pH 9.5 in 20% acetonitrile and 
transferred to 2 ml HPLC microvials containing 200 µl glass inserts. 
2.4.3. HCA quantification by LC-MS/MS 
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HCAs were separated on a BEH C18 1.7 µm column (50 × 2.1 mm) and Acquity UPLC® binary pump 
system and detected by Xevo TQS tandem mass spectrometer (Waters Corporation, Manchester, 
UK). Instrument settings and LC gradient were as published previously (Cooper et al., 2014). Injection 
volume was increased to 7 ml to maximise method sensitivity. HCA fragmentation transitions are 
listed in Table 2. Deuterium labelled internal standards were included in all samples prior to extraction 
and in solvent calibration standards to improve quantification by compensating for extraction 
efficiency and matrix ion suppression effects. However, D3-PhIP was omitted from quantification of 
PhIP due to an interfering peak eluting at the same retention time in acid hydrolysed plasma samples. 
HCA identification was based on peak retention time and the presence of both a primary (quantitative) 
ion transition peak and a secondary (confirmatory) peak, the ratio of which had to agree to within fixed 
tolerances of the corresponding ratio in standards (Cooper et al., 2014). Confidence in identification of 
an analyte is crucial when quantifying a low concentration biomarker, so strict ion ratio tolerances 
were applied (±30% for PhIP, 25% for MeIQx, 20% for 4,8-and 7,8-DiMeIQx) based on guidance in 
European Commission Decision 2002/657 for the analytical performance of methods in the veterinary 
pharmaceuticals field. While this document is not directly applicable to natural carcinogens such as 
HCAs, it is the opinion of the authors that similar identification criteria should be applied to analysis of 
suspected carcinogens whenever possible to avoid misidentification, particularly in methods involving 
acid hydrolysis which increases chromatogram background noise. 
2.4.4. LC-MS/MS method validation 
The analytical method employing the representative hydrolysis protocol described below was 
validated using a pool of nominally blank plasma obtained from participants with the lowest HCA 
intake based on their 7-day food diaries. Seven aliquots of pooled plasma were fortified with HCAs at 
10 pg/ml, extracted and quantified as described above. This was repeated on three days to enable 
calculation of intra- and inter-assay variations (% RSD). Limits of detection (LOD) and quantification 
(LOQ) were calculated based on signal-to-noise (s/n) ratios of the least intense transition peak for 
each HCA, using unsmoothed peaks (LOD s/n >3, LOQ s/n >10). In vitro HCA-protein adducts were 
used as positive controls to prove the efficacy of the hydrolysis and extraction procedures. Blank 
plasma was fortified with in vitro adducts at 3-20 pg/ml based on the measured acid-labile HCAs 
incorporated in the adducts (Table 3). 
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3. Results 
3.1. Characterisation of in vitro HCA-protein adducts 
Incorporation of acid-labile HCAs into human blood proteins following in vitro incubation with human 
hepatic microsomes is shown in Table 3. HCAs released by acid hydrolysis (0.8M HCl at 80°C for 2 h) 
and liquid-liquid extraction with ethyl acetate ranged from 6.5 to 23.5 ng HCA/mg protein. 
3.2. LC-MS/MS method validation 
LC-MS/MS chromatograms illustrating the quantitative and confirmatory transition peaks for each of 
the four HCAs fortified into plasma at 5 pg/ml prior to acid hydrolysis and extraction are shown in 
Figure 1. Analytical method validation data are listed in Table 4. Assay performance was acceptable 
with all RSDs below 10%, recovery of fortified HCAs ranging from 91-116% and limits of detection 
ranging from 1-5 pg/ml plasma. PhIP LOD was higher than other HCAs due to the low intensity of its 
confirmatory peak (Figure 1). Solvent calibration curve linearity was typically r2>0.98 over the range 
equivalent to 1-30 pg/ml plasma. The efficacy of the validated hydrolysis and extraction protocol was 
demonstrated by fortifying blank plasma with HCA-protein adducts synthesised in vitro. Recovery of 
HCAs adducted to HSA and Hb was on average 65% for PhIP and 114% for MeIQx based on acid-
labile HCAs incorporated in the adducts (Table 3). 
3.3. Hydrolysis method selection 
None of the four HCAs was observed and confirmed in the plasma pool of high intake participants 
following any of the nine hydrolysis conditions described (Table 1). In order to analyse a wider range 
of individual plasmas from the highest HCA participants, a representative hydrolysis protocol was 
selected. It was observed that use of 6M HCl or incubation at 95°C resulted in higher background 
noise in chromatograms, potentially masking small HCA peaks. Hydrolysis using 2M HCl for 1h at 
80°C was chosen as the representative method (Busquets et al., 2006), supported by an earlier 
observation of a low concentration PhIP peak (confirmatory peak not visible) in a single plasma 
sample under similar conditions. 
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3.4. Cross-sectional study 
Blood samples and completed 7-day food diaries were obtained from 122 participants. Participants 
were categorised into tertiles based on estimated total HCA dietary intake (Table 5) which ranged 
from zero to 2.5 µg/d. 
3.5. Survey of acid-labile HCAs in plasma of high HCA intake participants 
Plasma from 35 participants with the highest HCA intakes (estimated 0.7-2.5 µg HCA/day) were 
tested for acid-labile HCA concentration using the representative hydrolysis protocol. Only one 
sample was confirmed to contain an acid-labile HCA above the analytical limits of detection: PhIP at 
9.7 pg/ml plasma from a participant with estimated HCA intake of 0.9 µg/day. Serum from the same 
participant contained acid-labile PhIP at 8.1 pg/ml. The paucity of acid-labile HCAs led us to revisit the 
sample preparation method of Magagnotti et al. (2000) who isolated serum albumin by precipitation 
before hydrolysis with 0.1M HCl for 1h at 80°C followed by liquid-liquid extraction with ethyl acetate 
and clean up by immunoaffinity chromatography (as opposed to solid phase extraction used in the 
current study). We purified 75mg albumin from a pool of serum from high HCA intake participants 
(mean intake 1.8 µg/d) using ammonium sulphate/acetic acid precipitation before hydrolysis under 
Magagnotti’s conditions and extraction by our described method. No acid-labile HCAs were detected 
in this purified albumin sample. 
4. Discussion 
Residues of HCAs adducted to blood proteins have been postulated for some years as potential 
medium-term biomarkers of carcinogenic HCA exposure (Peng and Turesky, 2011; Magagnotti et al., 
2000; Dingley et al., 1999). However, the viability of quantifying HCAs following their release from 
such adducts in vivo has not been proven in people consuming diets encompassing the normal range 
of HCA intakes. To act as meaningful biomarkers, HCAs released from blood proteins must correlate 
with the known HCA exposure of the individual – primarily their dietary intake in non-smokers. To this 
end, blood samples were collected from 122 participants along with detailed food intake diaries, which 
demonstrated estimated HCA dietary intakes ranging from zero to 2.5 µg/d. A highly sensitive liquid 
chromatography tandem mass spectrometry method was developed and validated for the major 
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HCAs in plasma. An extensive range of hydrolysis conditions was examined for the release of 
adducted HCAs in plasma from participants with the highest HCA intakes. A HCA (PhIP at 9.7 pg/ml) 
was detected in only one plasma sample (participant HCA intake 0.9 µg/d), demonstrating 
conclusively, to our knowledge for the first time, that acid-labile HCA-blood protein adducts do not 
reflect dietary HCA intake and are present at such low concentrations that they are not suitable 
biomarkers of dietary exposure to HCAs. 
    In vitro control adducts of HCAs in blood proteins were prepared by incubation with human hepatic 
microsomes. Acid-labile MeIQx in albumin was higher by an estimated factor of five than observed by 
Lynch et al. (1993) in a similar system, presumably due to our longer reaction time and greater 
excess of starting MeIQx, since Lynch demonstrated in vitro adduction was time and concentration 
dependent. Lynch et al. (1993) also demonstrated that in vitro MeIQx adducts were approximately 
twice as likely to be hydrolysed to intact MeIQx from haemoglobin than from albumin adducts. This 
was not evident for MeIQx in the current study, but was seen with PhIP adducts. It is generally 
thought that total HCA adduction to albumin in vivo is substantially greater than to haemoglobin 
(Turesky and Le Marchand, 2011); however, one study (Magagnotti et al., 2000) demonstrated acid 
labile PhIP-Hb adducts to be only two-fold lower than albumin adducts. Our protein adducts prepared 
in vitro contain HCAs at concentrations approximately four orders of magnitude greater than PhIP-
protein adducts described in vivo in the few studies which have quantified albumin or haemoglobin 
adducts in people consuming conventional diets (Magagnotti et al., 2000) or dietary-relevant doses of 
radiolabelled PhIP (Dingley et al., 1999). This high level of adduction is similar to that reported for in 
vitro adduction of reactive metabolites of PhIP to albumin (Peng and Turesky, 2011). 
    The analytical method applied in this study (adduct hydrolysis, HCA extraction by liquid-liquid 
extraction, clean-up by solid phase extraction and quantification by UPLC-MS/MS) was demonstrated 
to be fit-for-purpose by several means. Firstly, validation of the method using plasma repeatedly 
fortified with HCAs and isotopically labelled internal standards at low concentrations demonstrated 
satisfactory assay performance (analyte recovery, reproducibility and repeatability) and excellent 
sensitivity, limits of detection ranging from 1 to 5 pg HCA per ml plasma. Secondly, HCA-protein 
adducts were synthesised in vitro and used to demonstrate the method was capable of releasing 
intact HCAs by hydrolysis and extracting them quantitatively from plasma at low parts-per-trillion 
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concentrations. Thirdly, the widest range of HCA hydrolysis conditions yet published was examined, 
encompassing, but not limited to, published conditions from diverse in vitro and in vivo HCA-adduct 
studies. While the HCA-protein literature concentrates on acidic hydrolysis conditions, we also 
included selected alkaline conditions (previously applied to hydrolysis of DNA and melanin adducts of 
HCAs) to give the broadest opportunity for liberation of protein-bound HCAs. Fourthly, the finding of 
PhIP in a single plasma sample demonstrated the method was capable of detecting acid-labile PhIP 
in participants with normal dietary intakes. 
    Confidence in the identification of analytes is crucial when measuring low concentrations of 
compounds in complex biological matrices, particularly compounds such as HCAs which share 
common structures and fragmentation patterns, and samples undergoing hydrolysis which increases 
chromatogram background noise. The presence of a second fragmentation peak to confirm an 
analyte’s identity should be a prerequisite in such analyses, although this is not always the case in the 
published literature of HCAs. The current study insisted on the presence of secondary peaks and 
included these in the calculation of limits of detection. Furthermore, the ratio of confirmatory to 
primary quantitation peaks (ion ratio) was monitored in every sample to ensure agreement with the 
same ratio in calibration standards. 
    Magagnotti et al. (2000) is currently the only study to have quantified a HCA (PhIP) following 
hydrolysis of blood proteins from humans consuming conventional diets. They observed 1.5 pg 
PhIP/mg HSA (equivalent to approximately 70 pg PhIP/ml plasma) in meat-eating participants after 
mild acid hydrolysis of 100 mg purified albumin, and PhIP concentrations ten-fold lower in vegetarian 
participants. The methodology described in the current study is easily capable of measuring such 
quantities, with HCA limits of detection from 1 to 5 pg/ml plasma. It should be highlighted that 
Magagnotti et al. (2000) did not monitor a secondary peak for PhIP, which could cast doubt on the 
identification of this analyte. The secondary fragment of PhIP (m/z 225.2>183.2) yields a peak 
approximately ten-fold less intense than the primary peak used to quantify the compound. Magagnotti 
reported a PhIP limit of detection similar to that of our current study but without the presence of this 
confirmatory peak. Thus, our method is capable of confirming the presence of HCAs in plasma to a 
significantly greater degree of certainty. To our knowledge the work of Magagnotti has not been 
reproduced in the scientific literature. The relative silence in the literature concerning validated HCA-
protein biomarkers, which have been discussed for over two decades, suggests that other 
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researchers have been unable to build on the promise of this study. The identification and validation 
of a labile HCA-protein biomarker is undoubtedly hampered by evidence that less than 10% of 
material derived from HCAs and bound to protein in vivo can be hydrolysed to the intact HCA (Lynch 
et al., 1993; Turesky et al., 1987). 
    A review of potential HCA biomarkers by Prof Robert Turesky et al. (2011) stated that “the 
inefficient binding of HCAs to haemoglobin will probably preclude the development of HCA-Hb 
adducts as biomarkers in humans”, and “…it is unlikely that the sulfinamide adduct of MeIQx with 
human serum albumin can be used as a dosimeter for human…exposure.” Prof Turesky continued, 
saying “further investigations on the implementation of PhIP blood protein adducts in human 
population studies are warranted.” In the opinion of the authors, the current study provides conclusive 
proof for the first time, using state-of-the-art mass spectrometry, that blood plasma protein adducts of 
both PhIP and MeIQx, even if they are present in significant concentrations in people consuming 
normal diets, are insufficiently acid-labile to yield intact HCAs which may act as biomarkers of HCA 
exposure. 
    Recent HCA biomarker studies have focused on detection and characterization of HCA-DNA 
adducts (Tang et al., 2013; Gu et al., 2012; Brown et al., 2001) which reflect the actual detrimental 
impact of these carcinogens at the genomic level rather than the indicative harm represented by 
protein adducts. Other studies are aiming to detect HCA-peptide adducts following proteolysis by 
stabilising the adduct’s arylsulfinamide bond via oxidation to an arylsulfonamide bond which is 
resistant to acid, heat and reducing agents commonly used in proteolytic digestion (Peng et al., 2012; 
Peng and Turesky 2013; 2014). While characterization of such stabilised adducts is ongoing (Peng 
and Turesky, 2014), their existence has yet to be demonstrated in human blood in vivo. However, an 
alternative approach is also warranted. Markers of HCA status, or more general dietary factors such 
as red meat intake, may be revealed via untargeted proteomic, lipidomic or metabolomic analyses. 
Preliminary metabolomic studies of the cohort of blood samples collected in this study are currently 
underway at the Institute for Global Food Security at Queen’s University Belfast. 
5. Conclusions 
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Carcinogenic and mutagenic heterocyclic aromatic amines are known to form adducts with blood 
proteins. The characterisation and use of such adducts as internal dosimeters in epidemiological 
studies of HCA exposure have been studied for many years without a clear candidate adduct being 
proven in vivo. The hydrolytic release from protein adducts of intact HCAs which distinguished 
between vegetarians and meat-eaters was demonstrated fifteen years ago (Magagnotti et al., 2000) 
but correlation with dietary HCA intake by this method has not been repeated since. The current study 
systematically assessed a range of hydrolysis conditions for release of HCAs from in vivo plasma 
adducts measured by validated mass spectrometry (limits of detection 1-5 pg/ml plasma). Food 
diaries from cross-sectional study participants demonstrated HCA intakes ranging from 0-2.5 µg/day. 
Despite sufficient assay sensitivity and use of positive control HCA-protein adducts synthesised in 
vitro, a HCA was detected in only one sample (PhIP, 9.7 pg/ml) demonstrating that acid-labile HCA 
adducts do not reflect dietary HCA intake as previously postulated and are present at such low 
concentrations that they are not viable biomarkers of HCA exposure. This conclusion is in keeping 
with the current direction of research in this area which aims to fully characterize the structure of HCA-
protein adducts and to utilize stabilised HCA-peptide adducts as dosimeters following protein 
digestion. 
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Highlights 
 
• Sensitive LC-MS/MS method validated for carcinogenic food-derived heterocyclic aromatic 
amines in plasma (LoD 1-5 pg/ml). 
• Extensive range of hydrolysis procedures demonstrated HCAs released from plasma protein 
adducts in only 1 of 122 samples. 
• Acid-labile HCAs adducted to blood proteins are not viable biomarkers of HCA dietary 
exposure. 
• Search for HCA biomarkers should concentrate on stabilised HCA-peptide markers and 
emerging untargeted -omic approaches. 
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Tables 
 
 
 
 
Table 1. Acid (hydrochloric acid, HCl) and alkaline (sodium hydroxide, NaOH) hydrolysis conditions 
assessed for release of protein-adducted HCAs from human plasma pooled from high HCA intake 
participants. 
Acid / Alkali Time (h) Temp.(°C) Reference Reference target analytes 
0.1M HCl 1 80 Magagnotti et al., 2000 PhIP/MeIQx in vivo HSA/Hb adducts 
0.2M HCl 1 37 Peng & Turesky, 2011 PhIP in vitro HSA adducts 
0.5M HCl 18 37 Lynch et al., 1991 MeIQx in vitro Hb adducts 
2M HCl 1 80 Busquets et al., 2006 PhIP in vitro fortified Hb 
2M HCl 18 95 Current study * 
6M HCl 2 80 Current study * 
6M HCl 3 95 Kataoka et al., 2010 PhIP cooked meat/fish protein adducts 
0.5M NaOH 18 95 Crosbie et al., 2000 PhIP in vitro cell culture DNA adducts 
1M NaOH 2 80 Bessette et al., 2009 PhIP in vivo hair melanin adducts 
 
 
22 
 
 
 
 
 
 
Table 2. Heterocyclic aromatic amine LC-MS/MS fragmentation conditions. 
Analyte tR (min) Primary transition (m/z) Confirmatory 
transition (m/z) 
Collision energy (V) 
PhIP 2.21 225.2>210.1 225.2>183.2 26 / 28 
   D3-PhIP 2.21 228.2>210.1 * 28 
MeIQx 1.07 214.2>199.1 214.2>131.1 24 / 36 
   D3-MeIQx 1.07 217.1>199.2 * 26 
7,8-DiMeIQx 1.31 228.2>131.1 228.2>213.1 36 / 24 
4,8-DiMeIQx 1.38 228.2>212.0 228.2>213.1 35 / 26 
   D3-4,8-DiMeIQx 1.38 231.2>213.1 * 24 
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Table 3. Acid-labile heterocyclic aromatic amines incorporated into human proteins following in vitro 
incubation with human hepatic microsomes and exhaustive dialysis. HCAs were quantified by LC-
MS/MS following acid hydrolysis and liquid-liquid extraction. 
HCA Protein ng HCA/mg protein 
PhIP Albumin 9.1 
PhIP Haemoglobin 23.5 
MeIQx Albumin 7.9 
MeIQx Haemoglobin 6.5 
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Table 4. Assay validation parameters for the hydrolysis (2M HCl, 1h, 80°C), extraction and 
quantification by LC-MS/MS of HCAs fortified in human plasma at 10 pg/ml. 
 PhIP MeIQx 7,8-DiMeIQx 4,8-DiMeIQx 
Mean recovery (%)a 90.7 115.5 105.7 103.4 
Mean within day RSDb (%) 6.7 8.8 4.2 4.7 
Between day RSD (%) 7.9 8.8 6.8 5.0 
Limit of detection (pg/ml) 5 2 1.5 1 
Limit of quantification (pg/ml) 15 5 4 2 
a Internal standard corrected recovery, except for PhIP where d3-PhIP was omitted 
b Relative Standard Deviation 
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Table 5. Cross-sectional study participants (n=122) categorised in tertiles by total dietary HCA intake 
(ng/day) estimated from 7-day food diaries. 
 HCA tertile 1 (n=41) HCA tertile 2 (n=40) HCA tertile 3 (n=41) 
Mean age (years, SD) 32.8 (9.5) 34.0 (13.4) 30.1 (10.9) 
Male (n, %) 18 (43.9) 16 (40.0) 13 (31.7) 
Female (n, %) 23 (56.1) 24 (60.0) 28 (68.3) 
    
Mean HCA intake (ng/d, SD)   
MeIQx 29.3 (30.0) 102.2 (55.8) 201.8 (104.9) 
DiMeIQx 12.9 (23.5) 18.4 (17.3) 44.2 (34.8) 
PhIP 53.6 (50.1) 344.4 (135.9) 912.0 (349.9) 
Total HCA  95.8 (70.6) 464.9 (149.8) 1157.6 (431.9) 
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Figure 1. ESI–LC–MS/MS MRM chromatograms of primary quantitation and secondary confirmatory 
peaks of four heterocyclic aromatic amines extracted from human plasma fortified at 5 pg/ml. 
Samples were acid hydrolysed (2M HCl, 1 h, 80°C) and extracted with ethyl acetate and cation 
exchange SPE. Analyte names, m/z transitions and peak heights are listed. 
 
